The effects of COVID-19 infection on the mortality of patients receiving rituximab therapy

BACKGROUND: Rituximab (RTX) is an important immunosuppressive agent used for many rheumatologic diseases. This study investigated the factors affecting mortality and mortality due to COVID-19 infection in patients receiving RTX. METHODS: From March 2020 to November 2021, 111 patients who were follow...

Descripción completa

Detalles Bibliográficos
Autores principales: Ekin, Ali, Coskun, Belkıs Nihan, Dalkilic, Ediz, Pehlivan, Yavuz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579651/
https://www.ncbi.nlm.nih.gov/pubmed/36258064
http://dx.doi.org/10.1007/s11845-022-03193-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579651/
https://www.ncbi.nlm.nih.gov/pubmed/36258064
http://dx.doi.org/10.1007/s11845-022-03193-6

Ejemplares similares